PortfoliosLab logo
Histogen Inc. (HSTO)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

US43358Y1038

CUSIP

43358Y103

IPO Date

Jul 25, 2013

Highlights

Market Cap

$85.44K

EPS (TTM)

-$2.81

Year Range

$0.02 - $0.32

Target Price

$2.00

Short %

1.62%

Short Ratio

4.25

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Histogen Inc.

Performance

Performance Chart


Loading data...

S&P 500

Returns By Period


HSTO

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

3Y*

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

0.51%

1M

6.15%

6M

-2.00%

1Y

12.92%

3Y*

12.68%

5Y*

14.19%

10Y*

10.85%

*Annualized

Monthly Returns

The table below presents the monthly returns of HSTO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202510.80%10.80%
202413.75%-10.00%14.32%-2.50%-51.01%74.42%-26.67%1.14%-2.25%-2.30%-90.59%25.00%-91.88%
202328.92%-5.61%19.80%-31.36%4.02%-17.70%4.20%-8.77%-23.88%-37.23%5.26%-9.50%-62.93%
2022-28.61%0.59%4.65%-25.64%-8.18%-33.22%18.42%-25.93%-32.50%-2.22%-22.73%-18.63%-87.53%
202151.72%-1.74%15.04%-10.77%-14.65%10.09%-17.79%-11.81%-4.13%-7.46%-31.55%-30.69%-56.11%
20209.00%-9.38%-21.51%14.96%21.18%-11.81%-24.67%-30.31%-18.00%3.05%-5.92%-52.33%-81.05%
201934.68%-16.74%-44.33%-20.37%-10.19%-66.33%22.41%7.41%-7.89%7.94%8.71%8.23%-76.88%
201820.35%-6.47%12.88%-41.91%26.10%-0.47%-5.37%38.52%3.39%-28.45%7.95%-61.38%-62.55%
2017-18.03%12.73%18.48%44.89%-41.03%16.84%-3.99%3.80%-4.36%-16.39%-9.59%11.33%-12.33%
2016-39.58%2.30%20.22%34.11%-19.86%-10.43%9.71%-19.91%10.50%-11.50%2.26%191.16%82.99%
2015-16.43%8.72%11.95%-16.43%-8.40%-5.50%-7.96%-17.09%13.23%-11.01%-19.44%-9.72%-58.86%
201463.88%6.15%-27.50%-24.40%0.65%47.17%-13.39%-12.67%-11.18%17.65%18.19%-17.74%8.53%
Go deeper with the Portfolio Analysis tool — backtest performance, assess risk, compare to benchmarks, and more

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of HSTO is 31, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of HSTO is 3131
Overall Rank
The Sharpe Ratio Rank of HSTO is 2626
Sharpe Ratio Rank
The Sortino Ratio Rank of HSTO is 5252
Sortino Ratio Rank
The Omega Ratio Rank of HSTO is 6868
Omega Ratio Rank
The Calmar Ratio Rank of HSTO is 22
Calmar Ratio Rank
The Martin Ratio Rank of HSTO is 44
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Histogen Inc. (HSTO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


There isn't enough data available to calculate the Sharpe ratio for Histogen Inc.. This metric is based on the past 12 months of trading data. Please check back later for updated information.


Loading data...

Go to the full Sharpe Ratio tool to analyze any stock or portfolio. Customize time frames, set your own risk-free rate, and more

Dividends

Dividend History


Histogen Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Histogen Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Histogen Inc. was 100.00%, occurring on Nov 21, 2024. The portfolio has not yet recovered.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-100%Jan 13, 20142735Nov 21, 2024
-43.18%Sep 27, 201352Dec 10, 201321Jan 10, 201473
-10.81%Aug 6, 201324Sep 9, 20137Sep 18, 201331
-7.19%Jul 29, 20135Aug 2, 20131Aug 5, 20136
-4.29%Sep 24, 20131Sep 24, 20131Sep 25, 20132
Go to the full Drawdowns tool for more analysis options, including inflation-adjusted drawdowns, and more

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Histogen Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Histogen Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -66.7%.


-35.00-30.00-25.00-20.00-15.00-10.00-5.000.00AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJuly
-0.90
-0.54
Actual
Estimate

Valuation

The Valuation section provides an overview of how Histogen Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for HSTO relative to other companies in the Biotechnology industry. Currently, HSTO has a P/S ratio of 4.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for HSTO in comparison with other companies in the Biotechnology industry. Currently, HSTO has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items